The document discusses human papilloma virus (HPV) including the virus itself, associated diseases, transmission, epidemiology, clinical manifestations, carcinogenic properties, vaccination, and treatment options. HPV is a common virus that can cause genital warts and various cancers like cervical cancer. Vaccination provides high efficacy against HPV types known to cause cancer and genital warts. Treatment depends on the manifestation but may include cryotherapy, laser ablation, or topical medications.

1. HUMAN PAPILLOMA VIRUS Dr.Abdulrahman Lotfy Preventive Medicine Jahra Hospital

2. HPV-THE VIRUS HPV-THE INFECTIOUS DISEASE HPV-THE CARCINOGEN HPV/CANCER-THE VACCINE

3. HPV-THE VIRUS

5. HPV-THE INFECTIOUS DISEASE

6. Human Papillomavirus Types and Disease Association

8. HPV-Associated Disease

17. Women: Genital warts usually start to appear appear on the vulva, in the vagina, on the cervix, or in the anal area

18. In men, they appear on the foreskin, head or shaft of the penis, and in the anal area, urethra, and scrotum

22. SUPERFICIAL (Flat) WARTS

23. PLANTAR WARTS

24. GENITAL CONDYLOMAS

25. INTERNAL WARTS Also includes Laryngeal warts (not shown here)

26. COLORECTAL CONDYLOMAS

31. HPV-THE CARCINOGEN

32. 93% of all cervical neoplasia cases test are positive for HPV making it the leading the third leading killer among women Cancer: Predominant types: Co-factors: Skin carcinomas HPV-5, 8 U.V., genetic? Lower genital tract cancers HPV-16, 18, 31, 33 ??? Malignant transformation of respiratory papillomas HPV-6, 11 X-rays

34. HPV infections predisposes to Cervical Cancer

35. CANCER CERVIX

36. HPV/Cancer-THE VACCINE

38. Risk with different types of viruses 30, 31, 33, 35, 39, 45, 51 and 53 6, 11, 40, 42 – 44, 54, 61,70, 72 and 81

39. HPV Vaccine Efficacy* *Among 16-26 year old females. CIN – cervical intraepithelial neoplasia; AIS – adenocarcinoma in situ

43. Efficacy of Gardasil HPV induced lesions Cervical Cancer & Precancers (Grade 2/ 3) 1 Vulvar/ Vaginal Precancers (Grade 1- 3) 2 Genital Warts 2 Protection by QHPV 98% 100% 99% 1. The Future II Study Group. Lancet 2007; 369: 1861–68 2.Garland SM et al. New Engl J Med. 2007;356:1928–1943.